LIGAND PHARMACEUTICALS (LGND) Stock News
NASDAQ:LGND - Nasdaq - US53220K5048 - Common Stock - Currency: USD
LGND Latest News, Press Relases and Analysis
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics ...
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Channel Therapeutics Corporation (NYSE:CHRO) on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos) with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel. The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson. Under the merger agreement, Channel will acquire 100% of Pe
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results ...
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments.
Ligand to Present at Stifel 2024 Healthcare Conference
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment banking at Goldman Sachs
Mentions: PIRS
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down.
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ligand Pharmaceuticals (NASDAQ:LGND) just reported results for the second quart...
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Halozyme And Ligand — Two Leading Biotechs — Smash Quarterly Forecasts
Halozyme and Ligand beat second-quarter expectations late Tuesday. But only one of the biotech stocks jumped.
Mentions: HALO
Ligand Reports Second Quarter 2024 Financial Results
